Ceramides and risk of major adverse cardiovascular events: A meta-analysis of longitudinal studies

Recent cohort studies evaluated the association between some previously identified high-risk ceramides [Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/22:0), Cer(d18:1/24:0) and Cer(d18:1/24:1)] and risk of major adverse cardiovascular events in adult population. The objective of this meta-analysis was...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of clinical lipidology Ročník 14; číslo 2; s. 176 - 185
Hlavní autoři: Mantovani, Alessandro, Dugo, Clementina
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Elsevier Inc 01.03.2020
Témata:
Cardiovascular disease
Cardiovascular events
Ceramides
CVD
Major adverse cardiovascular events
CVD
Ceramides
Cardiovascular events
Cardiovascular disease
Major adverse cardiovascular events
ISSN:1933-2874, 1876-4789
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Recent cohort studies evaluated the association between some previously identified high-risk ceramides [Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/22:0), Cer(d18:1/24:0) and Cer(d18:1/24:1)] and risk of major adverse cardiovascular events in adult population. The objective of this meta-analysis was to investigate the magnitude of such associations. We searched publication databases using appropriate keywords to identify cohort studies (published up to July 30, 2019), in which association between previously identified high-risk ceramides and major adverse cardiovascular events was reported. Data from eligible studies were extracted and meta-analysis was performed using random-effects modeling. Seven cohort studies with aggregate data on 29,818 individuals (2736 new cases of cardiovascular events over a median follow-up of 6 years) were included. Higher plasma levels of Cer(d18:1/16:0) (random effects hazard ratio [HR] per standard deviation 1.21, 95% confidence interval [CI] 1.11–1.32, I2 = 88%), Cer(d18:1/18:0) (HR 1.19, 95% CI 1.10–1.27, I2 = 68%), and Cer(d18:1/24:1) (HR 1.17, 95% CI 1.08–1.27, I2 = 83%) were associated with major adverse cardiovascular events. Conversely, no association with plasma levels of Cer(d18:1/22:0) (HR 1.14 95% CI 0.88–1.47, I2 = 88%) and Cer(d18:1/24:0) (HR 0.97, 95% CI 0.89–1.05, I2 = 73%) was found. Subgroup analyses did not substantially modify the findings. Higher plasma levels of Cer(d18:1/16:0), Cer(d18:1/18:0) and Cer(d18:1/24:1) were associated with major adverse cardiovascular events, whereas plasma levels of Cer(d18:1/22:0) and Cer(d18:1/24:0) were not. Additional research is required to elucidate the different role of ceramides on pathways involved in cardiovascular disease. •The magnitude of the association between ceramides and CVD remains uncertain.•Cer16, Cer18, and Cer24:1 were associated with CVD.•No association with Cer22 and Cer24:0 was observed.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1933-2874
1876-4789
DOI:10.1016/j.jacl.2020.01.005